Melanoma Patient Thrives on Personalized Russian Vaccine

The initial patient administered with Russia's novel personalized melanoma vaccine, Neooncovac, is reported to be in good health and has successfully generated the required immune response. This groundbreaking mRNA-based treatment, a collaborative effort involving the Gamaleya Research Institute, received approval from the Russian Health Ministry last year.

This personalized approach involves analyzing a patient's tumor and healthy tissue to create a custom vaccine. The goal is to educate the immune system to recognize and combat cancer cells and their metastases. The first recipient, a 60-year-old man with stage-three melanoma, is continuing his treatment and showing positive immunological indicators.

Further personalized melanoma vaccines are being prepared for ten additional patients, with readiness anticipated within one-and-a-half to three months. The Gamaleya Institute is also developing treatments for other cancers, including pancreatic, kidney, and non-small cell lung cancer. Patients receiving another approved medicine, Oncopept for colorectal cancer, have also demonstrated the necessary immune responses.